Verastem, Inc. (NASDAQ:VSTM) has been given an average recommendation of “Hold” by the eight research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.10.
A number of research analysts recently commented on VSTM shares. Zacks Investment Research raised Verastem from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $6.00 price target on Verastem and gave the company a “buy” rating in a research note on Sunday, June 4th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price target on shares of Verastem in a research note on Thursday, June 8th. Cann reaffirmed a “buy” rating and issued a $6.00 price target on shares of Verastem in a research note on Monday, June 26th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $1.50 price target on shares of Verastem in a research note on Wednesday, June 28th.
Hedge funds have recently bought and sold shares of the stock. Alpine Woods Capital Investors LLC acquired a new position in Verastem in the second quarter valued at about $109,000. TFS Capital LLC acquired a new position in Verastem during the first quarter worth about $113,000. Northern Trust Corp raised its stake in Verastem by 40.3% during the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 21,178 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in Verastem during the second quarter worth about $234,000. Finally, Dimensional Fund Advisors LP raised its stake in Verastem by 697.6% during the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 253,492 shares in the last quarter. 24.19% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/09/17/brokerages-set-verastem-inc-vstm-pt-at-5-10.html.
Shares of Verastem (NASDAQ VSTM) traded up 0.74% during midday trading on Wednesday, hitting $5.41. 2,056,124 shares of the company were exchanged. The company has a 50-day moving average of $3.88 and a 200 day moving average of $2.63. Verastem has a one year low of $1.05 and a one year high of $5.71. The company’s market capitalization is $200.13 million.
Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). On average, equities research analysts expect that Verastem will post ($1.38) earnings per share for the current fiscal year.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.